Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F17%3A10336208" target="_blank" >RIV/00216208:11160/17:10336208 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/17:00096876 RIV/00216208:11130/17:10336208 RIV/65269705:_____/17:00066935 RIV/00064203:_____/17:10336208
Result on the web
<a href="http://link.springer.com/article/10.1007/s10198-015-0759-9" target="_blank" >http://link.springer.com/article/10.1007/s10198-015-0759-9</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s10198-015-0759-9" target="_blank" >10.1007/s10198-015-0759-9</a>
Alternative languages
Result language
angličtina
Original language name
Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study
Original language description
Economic data pertaining to cystic fibrosis (CF), is limited in Europe generally, and completely lacking in Central and Eastern Europe. We performed an analysis of all direct costs associated with CF relative to key disease features and laboratory examinations. A retrospective prevalence-based cost-of-illness (COI) study was performed in a representative cohort of 242 CF patients in the Czech Republic, which represents about 65 % of all Czech CF patients. Medical records and invoices to health insurance companies for reference year 2010 were analyzed. The mean total health care costs were EUR 14,486 per patient, with the majority of the costs going towards medicinal products and devices (EUR 10,321). Medical procedures (EUR 2676) and inpatient care (EUR 1829) represented a much smaller percentage of costs. A generalized linear model showed that the strongest cost drivers, for all cost categories, were associated with patient age and lung disease severity (assessed using the FEV1 spirometric parameter), when compounded by chronic Pseudomonas aeruginosa airway infections. Specifically, maximum total costs are around the age 16 years; a FEV1 increase of 1 % point represented a cost decrease of: 0.9 % (medicinal products), 1.7 % (total costs), 2.8 % (procedures) and 7.0 % (inpatient care). COI analysis and regression modeling using the most recent data available can provide a better understanding of the overall economic CF burden. A comparison of our results with other methodologically similar studies demonstrates that although overall costs may differ, FEV1 can nonetheless be utilized as a generally transferrable indicator of the relative economic impact of CF.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
<a href="/en/project/7E13069" target="_blank" >7E13069: An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
European Journal of Health Economics
ISSN
1618-7598
e-ISSN
—
Volume of the periodical
18
Issue of the periodical within the volume
1
Country of publishing house
DE - GERMANY
Number of pages
10
Pages from-to
73-82
UT code for WoS article
000392437100007
EID of the result in the Scopus database
2-s2.0-84953410327